WO2024179620A3 - 耐免疫排斥的工程化细胞 - Google Patents
耐免疫排斥的工程化细胞 Download PDFInfo
- Publication number
- WO2024179620A3 WO2024179620A3 PCT/CN2024/090859 CN2024090859W WO2024179620A3 WO 2024179620 A3 WO2024179620 A3 WO 2024179620A3 CN 2024090859 W CN2024090859 W CN 2024090859W WO 2024179620 A3 WO2024179620 A3 WO 2024179620A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- engineered cell
- immunosuppressive
- immune rejection
- domain
- resistant engineered
- Prior art date
Links
- 230000001506 immunosuppresive effect Effects 0.000 abstract 5
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102100026882 Alpha-synuclein Human genes 0.000 abstract 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 abstract 1
- 108010039471 Fas Ligand Protein Proteins 0.000 abstract 1
- 102000015212 Fas Ligand Protein Human genes 0.000 abstract 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 abstract 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 abstract 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 abstract 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 abstract 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 abstract 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 abstract 1
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 abstract 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 abstract 1
- 101150069255 KLRC1 gene Proteins 0.000 abstract 1
- 102000017578 LAG3 Human genes 0.000 abstract 1
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 abstract 1
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 abstract 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 abstract 1
- 230000000139 costimulatory effect Effects 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
一种免疫抑制分子，其包含免疫抑制蛋白结合结构域、跨膜结构域和共刺激结构域并且不包含初级信号传导结构域，其中所述免疫抑制蛋白选自NKG2A、TIM3、LAG3、TIGIT、CTLA4、PD1和FasL中的两种或两种以上。表达所述免疫抑制分子的工程化细胞以及包含该工程化细胞的组合物。用所述免疫抑制分子来降低免疫排斥的方法。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2023/079408 | 2023-03-02 | ||
| CN2023079408 | 2023-03-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2024179620A2 WO2024179620A2 (zh) | 2024-09-06 |
| WO2024179620A3 true WO2024179620A3 (zh) | 2024-10-24 |
Family
ID=92590012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2024/090859 WO2024179620A2 (zh) | 2023-03-02 | 2024-04-30 | 耐免疫排斥的工程化细胞 |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2024179620A2 (zh) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101952317A (zh) * | 2008-01-24 | 2011-01-19 | 诺沃-诺迪斯克有限公司 | 人化抗-人nkg2a单克隆抗体 |
| CN109804064A (zh) * | 2016-09-29 | 2019-05-24 | 南克维斯特公司 | 具有降低的免疫原性的hla i类缺陷的nk-92细胞 |
| CN114437214A (zh) * | 2020-11-03 | 2022-05-06 | 南京北恒生物科技有限公司 | 靶向lir1的抗体及其用途 |
| CN114524876A (zh) * | 2020-11-23 | 2022-05-24 | 南京北恒生物科技有限公司 | 靶向nkg2a的抗体及其用途 |
| CN114853900A (zh) * | 2021-02-03 | 2022-08-05 | 南京北恒生物科技有限公司 | 新型嵌合抗原受体及其用途 |
| WO2022257937A1 (zh) * | 2021-06-07 | 2022-12-15 | 南京北恒生物科技有限公司 | 用于细胞免疫治疗的方法和组合物 |
| CN117187185A (zh) * | 2022-05-31 | 2023-12-08 | 南京北恒生物科技有限公司 | 一种工程化免疫细胞及其用途 |
-
2024
- 2024-04-30 WO PCT/CN2024/090859 patent/WO2024179620A2/zh unknown
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101952317A (zh) * | 2008-01-24 | 2011-01-19 | 诺沃-诺迪斯克有限公司 | 人化抗-人nkg2a单克隆抗体 |
| CN109804064A (zh) * | 2016-09-29 | 2019-05-24 | 南克维斯特公司 | 具有降低的免疫原性的hla i类缺陷的nk-92细胞 |
| CN114437214A (zh) * | 2020-11-03 | 2022-05-06 | 南京北恒生物科技有限公司 | 靶向lir1的抗体及其用途 |
| CN114524876A (zh) * | 2020-11-23 | 2022-05-24 | 南京北恒生物科技有限公司 | 靶向nkg2a的抗体及其用途 |
| CN114853900A (zh) * | 2021-02-03 | 2022-08-05 | 南京北恒生物科技有限公司 | 新型嵌合抗原受体及其用途 |
| WO2022257937A1 (zh) * | 2021-06-07 | 2022-12-15 | 南京北恒生物科技有限公司 | 用于细胞免疫治疗的方法和组合物 |
| CN117187185A (zh) * | 2022-05-31 | 2023-12-08 | 南京北恒生物科技有限公司 | 一种工程化免疫细胞及其用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024179620A2 (zh) | 2024-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2019074973A3 (en) | Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies | |
| IL277242B1 (en) | Antibodies that bind cd39 and uses thereof | |
| IL273402B2 (en) | Antibodies against human leukocyte antigens type A2 and methods of using them | |
| WO1998050431A3 (en) | A method for making multispecific antibodies having heteromultimeric and common components | |
| WO2021041715A3 (en) | Compositions including igg fc mutations and uses thereof | |
| RU2019100481A (ru) | Биспецифические антитела-ингибиторы контрольных точек | |
| KR960704938A (ko) | Fas 길항제 및 그의 용도(Fas Antagonists and Uses Thereof) | |
| NZ574473A (en) | Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity | |
| EP2330120A3 (en) | Binding moieties based on Shark IgNAR domains | |
| JP2012514997A5 (zh) | ||
| RU2013140685A (ru) | ВАРИАНТЫ Fc, СПОСОБЫ ИХ ПОЛУЧЕНИЯ | |
| CA2185656A1 (en) | Protein tyrosine kinase agonist antibodies | |
| IL169152A (en) | Isolated antibody which binds to an epitope within the extracellular domain of pd - 1 | |
| WO2022226342A3 (en) | Modified anti-tslp antibodies | |
| WO2022162518A3 (en) | Psma binding proteins and uses thereof | |
| WO2024179620A3 (zh) | 耐免疫排斥的工程化细胞 | |
| WO2000023565A3 (en) | Novel neuropilin/growth factor binding and uses thereof | |
| MX2024015610A (es) | Variantes il-12, anticuerpos anti-pd1, proteinas de fusion y usos de estos | |
| EP1161955A3 (en) | Induction of immunological tolerance for graft transplantation by the use of humanized non-depleting anti-cd4 antibodies in combination with specific donor bone marrow cells | |
| WO2023133361A3 (en) | Anti-cthrc1 fusion proteins and methods of using the same | |
| GB9319877D0 (en) | Novel hybridoma & monoclonal antibodies produced thereby | |
| WO2021247457A3 (en) | Methods for making extracellular vesicles and uses thereof | |
| CA2133873A1 (en) | Tnf inhibitors | |
| WO2020226502A3 (en) | Variant domains for multimerizing proteins and separation thereof | |
| WO2024148232A3 (en) | Anti-il18 binding protein antibodies and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 24763300 Country of ref document: EP Kind code of ref document: A2 |